Clinical diagnostic value of targeted next generation sequencing for lower respiratory tract infection: a retrospective study
Frontiers in Cellular and Infection Microbiology · 08.07.2026 · 16
DOI: 10.3389/fcimb.2026.1713445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 08.07.2026. Verfasst von Yueyan Ni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing, China. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Respiratory Tract Infections. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Lower respiratory tract infections (LRTIs) progress swiftly and require timely, accurate pathogen detection to enhance patient outcomes. This study aims to utilize the targeted metagenomic next-generation sequencing (tNGS) technology as a novel approach to investigate the types of pathogens involved in infections following different structural lung diseases.
Methods
This retrospective cohort study enrolled 329 patients with suspected LRTIs admitted to three medical centers from June 2023 and June 2024. The study analyzed the pathogenic spectrum of lung infections and compared the diagnostic outcomes of tNGS with those of conventional microbiological techniques (CMTs). Results tNGS demonstrated significantly higher sensitivity (97.8% vs. 28.9%, p<0.05) and accuracy (96.6% vs. 30.3%, p<0.05) than CMTs, along with a high concordance rate (87.8%) with clinically confirmed pathogens. Pathogen profiling revealed that Mycoplasma pneumoniae (21.88%), Aspergillus fumigatus (5.17%), and influenza A virus subtype H3N2 (13.07%) were the predominant bacterial, fungal, and viral pathogens, respectively. Several key pathogens, including Pseudomonas aeruginosa , Haemophilus influenzae , Nocardia abscessus , Aspergillus fumigatus , Influenza A virus H3N2, and Influenza B virus, were detected more frequently in the SLD group than in the non-SLD group. Among 193 patients whose treatment was adjusted based on tNGS results, 35.2% initiated new treatment regimens, 25.4% continued their original treatment, and 7.3% required treatment escalation, with 90.2% of these patients showing clinical improvement.
Conclusion
These findings showed that tNGS demonstrates significant promise for the etiological diagnosis and tailored management of LRTIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Nanjing, China.
- Department of Medicine, Dinfectome Inc., Nanjing, China.
- Department of Respiratory and Critical Care Medicine, The First People's Hospital of Changzhou, Changzhou, China.
- Department of Respiratory and Critical Care Medicine, Changzhou Fourth People's Hospital, Changzhou, China.
- Department of Respiratory and Critical Care Medicine, Changzhou Third People's Hospital, Changzhou, China.
Zitieren
APA
Ni, Y., Wu, W., Liu, J., Feng, C., Jin, B., Zhao, T., Gu, Y., Su, X., Li, C., & Yuan, X. (2026). Clinical diagnostic value of targeted next generation sequencing for lower respiratory tract infection: a retrospective study. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1713445
Vancouver
Ni Y, Wu W, Liu J, Feng C, Jin B, Zhao T, et al. Clinical diagnostic value of targeted next generation sequencing for lower respiratory tract infection: a retrospective study. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1713445
BibTeX
@article{Ni2026,
author = {Ni, Yueyan and Wu, Weiwei and Liu, Jia and Feng, Chunlai and Jin, Bing and Zhao, Tingting and Gu, Yu and Su, Xin and Li, Chong and Yuan, Xin},
title = {Clinical diagnostic value of targeted next generation sequencing for lower respiratory tract infection: a retrospective study},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2026},
volume = {16},
doi = {10.3389/fcimb.2026.1713445}
}
EUVIMED